Kovack Advisors Inc. Has $2.03 Million Position in Pfizer Inc. $PFE

Kovack Advisors Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 2.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 83,708 shares of the biopharmaceutical company’s stock after selling 2,253 shares during the period. Kovack Advisors Inc.’s holdings in Pfizer were worth $2,029,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. Capital Advisors Inc. OK grew its holdings in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after purchasing an additional 17,032 shares during the last quarter. Westbourne Investments Inc. acquired a new position in Pfizer during the first quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. grew its holdings in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the last quarter. Strs Ohio acquired a new position in Pfizer during the first quarter valued at approximately $49,968,000. Finally, IFM Investors Pty Ltd grew its holdings in Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after purchasing an additional 41,263 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PFE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Up 0.0%

Shares of PFE stock opened at $24.30 on Friday. The stock has a market cap of $138.15 billion, a P/E ratio of 12.93, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.64. The stock has a fifty day moving average price of $24.80 and a 200 day moving average price of $24.25. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.